ERAMET (ER7.DE) Fundamental Analysis & Valuation

FRA:ER7 • FR0000131757

Current stock price

54.6 EUR
+2.65 (+5.1%)
Last:

This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ER7.DE Profitability Analysis

1.1 Basic Checks

  • ER7 had negative earnings in the past year.
  • In the past year ER7 has reported a negative cash flow from operations.
  • ER7 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years ER7 4 years had a positive operating cash flow.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • The Return On Assets of ER7 (-1.58%) is worse than 72.73% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.29%, ER7 is doing worse than 75.00% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 0.80%, ER7 is doing worse than 68.18% of the companies in the same industry.
  • ER7 had an Average Return On Invested Capital over the past 3 years of 7.29%. This is in line with the industry average of 8.77%.
  • The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROIC 0.8%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • ER7's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 1.91%, ER7 is doing worse than 63.64% of the companies in the same industry.
  • ER7's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.15%, ER7 belongs to the top of the industry, outperforming 93.18% of the companies in the same industry.
  • ER7's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.91%
PM (TTM) N/A
GM 68.15%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ER7.DE Health Analysis

2.1 Basic Checks

  • ER7 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ER7 has more shares outstanding
  • Compared to 5 years ago, ER7 has more shares outstanding
  • The debt/assets ratio for ER7 has been reduced compared to a year ago.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • ER7 has an Altman-Z score of 1.08. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.08, ER7 is doing worse than 84.09% of the companies in the same industry.
  • ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
  • ER7 has a worse Debt to Equity ratio (2.03) than 90.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 1.08
ROIC/WACC0.09
WACC9.36%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that ER7 should not have too much problems paying its short term obligations.
  • ER7 has a worse Current ratio (1.54) than 68.18% of its industry peers.
  • A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.
  • The Quick ratio of ER7 (1.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ER7.DE Growth Analysis

3.1 Past

  • The earnings per share for ER7 have decreased strongly by -219.63% in the last year.
  • Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.
  • The Revenue has decreased by -6.91% in the past year.
  • ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%

3.2 Future

  • ER7 is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.30% yearly.
  • Based on estimates for the next years, ER7 will show a small growth in Revenue. The Revenue will grow by 1.83% on average per year.
EPS Next Y-333.81%
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%
EPS Next 5Y-7.3%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y1.83%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. ER7.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • ER7's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.62
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

  • ER7's earnings are expected to decrease with -38.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ER7.DE Dividend Analysis

5.1 Amount

  • No dividends for ER7!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ER7.DE Fundamentals: All Metrics, Ratios and Statistics

ERAMET

FRA:ER7 (4/23/2026, 7:00:00 PM)

54.6

+2.65 (+5.1%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-18
Earnings (Next)04-23
Inst Owners16.96%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.57B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts78
Price Target52.84 (-3.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.96%
PT rev (3m)-4.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 2.91
EV/EBITDA 14.62
EPS(TTM)-3.42
EYN/A
EPS(NY)-6.23
Fwd EYN/A
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROCE 1.16%
ROIC 0.8%
ROICexc 0.95%
ROICexgc 1.09%
OM 1.91%
PM (TTM) N/A
GM 68.15%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA 10.29
Cap/Depr 403.31%
Cap/Sales 21.11%
Interest Coverage 0.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 1.08
F-Score2
WACC9.36%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-333.81%
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%
EPS Next 5Y-7.3%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y1.83%
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year-4.34%
EBIT Next 3Y26.47%
EBIT Next 5Y19.21%
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE Fundamental Analysis FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


What is the valuation status of ERAMET (ER7.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


How profitable is ERAMET (ER7.DE) stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.


How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.


What is the earnings growth outlook for ERAMET?

The Earnings per Share (EPS) of ERAMET (ER7.DE) is expected to decline by -333.81% in the next year.